Daniel Wilhelm Mueller
9 Papers
4 Citations
Daniel Wilhelm Mueller is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
The RENAISSANCE (AIO-FLOT5) Trial: Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of the German AIO/CAO-V/CAOGI
Salah-Eddin Al-Batran,Thorsten Oliver Goetze,Daniel Wilhelm Mueller,Arndt Vogel,Michael Winkler,Sylvie Lorenzen,Alexander Novotny,Claudia Pauligk,Nils Homann,Thomas Jungbluth,Christoph Reissfelder,Karel Caca,Steffen Retter,Eva Horndasch,Julia Gumpp,Claus Bolling,Karl-Hermann Fuchs,Wolfgang Blau,Winfried Padberg,Michael Pohl,A. Wunsch,Patrick Michl,Frank Mannes,Matthias Schwarzbach,Harald Schmalenberg,Michael Hohaus,Christian Wilfried Scholz,Christoph Benckert,Jorge Riera Knorrenschild,Veit Kanngießer,Thomas Zander,Hakan Alakus,Ralf Hofheinz,C. Roedel,Manish A. Shah,Mitsuru Sasako,Dietmar Lorenz,Jakob R. Izbicki,Wolf O. Bechstein,Hauke Lang,Stefan Paul Moenig +40 more
TL;DR: The RENAISSANCE trial as mentioned in this paper addresses the potential benefits of surgical intervention in gastric and gastroesophageal junction cancer with limited metastases, which is a prospective, multicenter, randomized, investigator-initiated phase III trial.
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III tri
Salah-Eddin Al-Batran,Thorsten Oliver Goetze,Daniel Wilhelm Mueller,Arndt Vogel,Michael Winkler,Sylvie Lorenzen,Alexander Novotny,Claudia Pauligk,Nils Homann,Thomas Jungbluth,Christoph Reissfelder,Karel Caca,Steffen Retter,Eva Horndasch,Julia Gumpp,Claus Bolling,Karl-Hermann Fuchs,Wolfgang Blau,Winfried Padberg,Michael Pohl,A. Wunsch,Patrick Michl,Frank Mannes,Matthias Schwarzbach,Harald Schmalenberg,Michael Hohaus,Christian Scholz,Christoph Benckert,Jorge Riera Knorrenschild,Veit Kanngießer,Thomas Zander,Hakan Alakus,Ralf-Dieter Hofheinz,C. Roedel,Manish A. Shah,Mitsuru Sasako,Dietmar Lorenz,Jakob R. Izbicki,Wolf O. Bechstein,Hauke Lang,Stefan Paul Moenig +40 more
- 01 Jan 2017
TL;DR: If the RENAISSANCE concept proves to be effective, this could potentially lead to a new standard of therapy and patients with gastric or GEJ cancer and metastases will no longer be considered candidates for surgical intervention.
106
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
Georg Martin Haag,Niels Halama,Christoph Springfeld,Barbara Grün,Leonidas Apostolidis,Stefanie Zschaebitz,Mareike Dietrich,Anne-Katrin Berger,Tim Frederik Weber,Inka Zoernig,Lisa Waberer,Daniel Wilhelm Mueller,Salah-Eddin Al-Batran,Dirk Jaeger +13 more
TL;DR: Checkpoint inhibition using PD-1/PD-L1 inhibitors does not show clinically relevant activity in MSS/pMMR (Mismatch Repair Proficient) colorectal cancer.
25
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Farastuk Bozorgmehr,Inn Chung,Petros Christopoulos,Johannes Krisam,Marc A. Schneider,Lena Brückner,Daniel Wilhelm Mueller,Mike Thomas,Stefan Rieken +8 more
TL;DR: The TRADE-hypo trial aims at optimizing treatment of elderly and frail patients suffering from unresectable stage III NSCLC by combining radiotherapy with concomitant durvalumab administration, thereby employing the immune-promoting effects of radiotherapy, and determining safety, feasibility, and efficacy of this treatment.
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
Thorsten Oliver Goetze,Daniel Wilhelm Mueller,Mohammad-Reza Rafiyan,Dragan Kiselicki,Regina Eickhoff,Elke Jaeger,Salah-Eddin Al-Batran +6 more
TL;DR: The INSPIRATION study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage oncology with promising results.
7